Table 1. Patient characteristics (n = 166).
| Baseline | No. | |
|---|---|---|
| Age (years) | <75 | 117 |
| ≥75 | 49 | |
| Gender | Male | 74 |
| Female | 92 | |
| Brinkman index | 0 | 89 |
| <600 | 37 | |
| ≥600 | 40 | |
| Performance status (ECOG) | 0 | 158 |
| 1 | 4 | |
| 2 | 4 | |
| Body Mass Index | <18.5 | 15 |
| 18.5 to <25 | 111 | |
| ≥25 | 40 | |
| Hugh-Jones classification | 1 | 154 |
| 2 | 9 | |
| 3 | 2 | |
| Surgical procedure | Wedge resection | 22 |
| Segmentectomy | 29 | |
| Lobectomy | 115 | |
| Lymphatic permeation | Absent | 149 |
| Present | 17 | |
| Vascular invasion | Absent | 146 |
| Present | 20 | |
| Pathological stage IA (T factor) | 1 (mi) | 36 |
| (1a) | 38 | |
| 2 (1b) | 56 | |
| 3 (1c) | 36 | |
| Pathological subtype | Minimally invasive adenocarcinoma | 36 |
| Lepidic | 70 | |
| Papillary | 38 | |
| Acinar | 12 | |
| Solid | 6 | |
| Others | 4 | |
| EGFR mutation | Negative | 57 |
| Positive | 47 | |
| Not recorded | 62 | |
| CEA (ng/mL) | ≤5 | 151 |
| >5 | 15 | |
| CRP (mg/dL) | ≤1 | 160 |
| >1 | 6 | |
| Albumin (g/dL) | ≥3.5 | 159 |
| <3.5 | 7 | |
| GPS | 0 | 156 |
| 1 | 7 | |
| 2 | 3 | |
| RDW | <13.3 | 97 |
| ≥13.3 | 69 | |
| PLR | <120 | 69 |
| ≥120 | 97 | |
| NLR | <3.43 | 143 |
| ≥3.43 | 23 | |
| ALI | ≥22.2 | 148 |
| <22.2 | 18 | |
| %VC (%) | ≥80 | 150 |
| <80 | 12 | |
| not recorded | 4 | |
| %FEV1.0 (%) | ≥80 | 136 |
| <80 | 26 | |
| Not recorded | 4 | |
| %DLCO (%) | ≥80 | 150 |
| <80 | 12 | |
| Not recorded | 4 | |
ECOG: eastern cooperative oncology group; EGFR: epidermal growth factor receptor; CEA: carcinoembryonic antigen; CRP: C-reactive protein; GPS: glasgow prognostic score; RDW: red cell distribution width; PLR: platelet-to-lymphocyte ratio; NLR: neutrophil-to-lymphocyte ratio; ALI: advanced lung cancer inflammation index; VC: vital capacity; FEV: forced expiratory volume; DLCO: diffusing capacity of lung carbon monoxide